Zila divests Zilactin
This article was originally published in The Tan Sheet
Executive Summary
Phoenix-based company sells its Zilactin brand of OTC lip and oral care products to Columbus, Ind.-based Blairex Laboratories for $10.3 mil. "plus agreed upon working capital adjustments," Zila announces June 27. The line includes Zilactin and Zilactin-B (benzocaine), both marketed for the treatment of cold sores, canker sores and fever blisters. The divestiture of the "non-strategic asset" is in line with Zila's plan to focus on "preventive healthcare technologies" such as its Ester-C and Ester-E supplement lines, according to the firm...